SG10202111785VA - Single-chain trail-receptor agonist proteins - Google Patents
Single-chain trail-receptor agonist proteinsInfo
- Publication number
- SG10202111785VA SG10202111785VA SG10202111785VA SG10202111785VA SG10202111785VA SG 10202111785V A SG10202111785V A SG 10202111785VA SG 10202111785V A SG10202111785V A SG 10202111785VA SG 10202111785V A SG10202111785V A SG 10202111785VA SG 10202111785V A SG10202111785V A SG 10202111785VA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor agonist
- agonist proteins
- chain trail
- trail
- chain
- Prior art date
Links
- 229940123369 TRAIL receptor agonist Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202111785VA true SG10202111785VA (en) | 2021-12-30 |
Family
ID=53055121
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202111785VA SG10202111785VA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
SG11201608767XA SG11201608767XA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
SG10201806465TA SG10201806465TA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608767XA SG11201608767XA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
SG10201806465TA SG10201806465TA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Country Status (37)
Country | Link |
---|---|
US (4) | US9908927B2 (en) |
EP (2) | EP3134430B1 (en) |
JP (2) | JP6523331B2 (en) |
KR (2) | KR20190135546A (en) |
CN (2) | CN106459221B (en) |
AR (1) | AR100168A1 (en) |
AU (3) | AU2015249649B2 (en) |
BR (1) | BR112016024515B1 (en) |
CA (2) | CA2946402C (en) |
CL (1) | CL2016002683A1 (en) |
CR (1) | CR20160516A (en) |
CY (1) | CY1120281T1 (en) |
DK (1) | DK3134430T3 (en) |
DO (1) | DOP2016000284A (en) |
EC (1) | ECSP16089579A (en) |
ES (1) | ES2672368T3 (en) |
HR (1) | HRP20180950T1 (en) |
HU (1) | HUE038914T2 (en) |
IL (2) | IL248244B (en) |
LT (1) | LT3134430T (en) |
MA (2) | MA45069A (en) |
MX (2) | MX2016013858A (en) |
MY (1) | MY181986A (en) |
NO (1) | NO2776305T3 (en) |
PE (1) | PE20170299A1 (en) |
PH (1) | PH12016502079B1 (en) |
PL (1) | PL3134430T3 (en) |
PT (1) | PT3134430T (en) |
RS (1) | RS57153B1 (en) |
RU (1) | RU2699285C2 (en) |
SG (3) | SG10202111785VA (en) |
SI (1) | SI3134430T1 (en) |
TR (1) | TR201806912T4 (en) |
TW (2) | TWI747178B (en) |
UA (1) | UA118286C2 (en) |
UY (1) | UY36095A (en) |
WO (1) | WO2015164588A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2745801C2 (en) * | 2015-05-04 | 2021-04-01 | Аподжиникс Аг | Single-stranded cd40 receptor agonist proteins |
JP6873119B2 (en) * | 2015-10-23 | 2021-05-19 | アポジェニックス アーゲー | Single-stranded LIGHT receptor agonist protein |
CA3002741A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain gitr-receptor agonist proteins |
CN108430492B (en) | 2015-10-23 | 2022-05-03 | 阿珀吉科吉尼科斯股份公司 | Single-chain CD27 receptor agonist proteins |
WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
WO2017151707A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
JP2019518713A (en) * | 2016-03-16 | 2019-07-04 | メリマック ファーマシューティカルズ インコーポレーティッド | Modified TRAIL for Cancer Therapy |
US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
EP3468580A4 (en) * | 2016-06-13 | 2020-02-26 | Merrimack Pharmaceuticals, Inc. | Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
CN111050784B (en) * | 2017-08-11 | 2024-03-19 | 伊利诺伊大学理事会 | Truncated guinea pig L-asparaginase variants and methods of use thereof |
WO2019178438A1 (en) * | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of cancer |
WO2019178433A1 (en) * | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
EP4149964A2 (en) | 2020-05-15 | 2023-03-22 | Apogenix AG | Multi-specific immune modulators |
AU2022281108A1 (en) | 2021-05-28 | 2023-12-14 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1226173A1 (en) | 1999-10-07 | 2002-07-31 | Maxygen Aps | Single-chain antagonist polypeptides |
DE19963859A1 (en) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins |
CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7538088B2 (en) | 2002-04-26 | 2009-05-26 | California Institute Of Technology | Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide |
DE102004014983A1 (en) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Recombinant polypeptides of the members of the TNF ligand family and their use |
US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
WO2006109301A2 (en) | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
EP2484691B1 (en) | 2007-07-10 | 2016-01-13 | Apogenix GmbH | TNF superfamily collectin fusion proteins |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
DK2604693T3 (en) * | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
AU2009293545A1 (en) | 2008-09-22 | 2010-03-25 | Amgen Inc. | Method of treatment |
CN102317314A (en) * | 2008-10-10 | 2012-01-11 | 阿纳福公司 | Polypeptides that bind TRAIL-RI and TRAIL-R2 |
ES2593049T3 (en) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Fusion proteins that form trimers |
US20120100140A1 (en) * | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
TW201130511A (en) | 2009-12-22 | 2011-09-16 | Novartis Ag | Soluble proteins for use as therapeutics |
US20130079280A1 (en) | 2010-04-13 | 2013-03-28 | Medlmmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
AU2012356894B2 (en) | 2011-12-23 | 2018-01-18 | Innate Pharma | Enzymatic conjugation of polypeptides |
US9434783B2 (en) | 2012-07-18 | 2016-09-06 | Apogenix Ag | Shortened CD95-Fc variant fusion proteins, nucleic acids and host cells thereof |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 MA MA045069A patent/MA45069A/en unknown
- 2015-04-23 RS RS20180450A patent/RS57153B1/en unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 AR ARP150101224A patent/AR100168A1/en active IP Right Grant
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 PT PT157210899T patent/PT3134430T/en unknown
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 PL PL15721089T patent/PL3134430T3/en unknown
- 2015-04-23 UA UAA201611802A patent/UA118286C2/en unknown
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/en active IP Right Grant
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/en not_active Application Discontinuation
- 2015-04-23 MA MA039770A patent/MA39770A/en unknown
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/en unknown
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/en active
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/en unknown
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/en active Active
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/en active Active
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/en active Active
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en active Application Filing
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/en active IP Right Grant
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/en unknown
- 2015-04-23 TW TW109106778A patent/TWI747178B/en active
- 2015-04-23 TW TW104113087A patent/TWI683825B/en active
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en active Active
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/en active IP Right Grant
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/en active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/en unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/en active Pending
- 2015-04-23 CR CR20160516A patent/CR20160516A/en unknown
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/en unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/en unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/en unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/en unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/en unknown
- 2018-06-19 HR HRP20180950TT patent/HRP20180950T1/en unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en active Active
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/en active Active
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272612A (en) | Single-chain trail-receptor agonist proteins | |
HK1232136A1 (en) | P97-ids fusion proteins p97-ids | |
SG11201704010UA (en) | Fibroin-derived protein composition | |
HUE050893T2 (en) | Protein | |
GB201415344D0 (en) | Protein | |
GB201515745D0 (en) | Proteins | |
GB201511787D0 (en) | Proteins | |
IL250502B (en) | New polypeptides | |
IL248276A0 (en) | Carbohydrate-binding protein | |
PL3099793T3 (en) | Protein | |
GB201513033D0 (en) | Proteins | |
SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
GB201517390D0 (en) | Protein variant analysis | |
GB201504048D0 (en) | Material sampler | |
GB201412797D0 (en) | Proteins | |
GB201412648D0 (en) | Proteins | |
GB201412646D0 (en) | Proteins | |
GB201412649D0 (en) | Proteins | |
GB201406894D0 (en) | Proteins | |
GB201515744D0 (en) | Proteins | |
GB201405952D0 (en) | Proteins | |
GB201405955D0 (en) | Proteins | |
GB201403913D0 (en) | Proteins | |
GB201403912D0 (en) | Proteins | |
GB201403915D0 (en) | Proteins |